BWAY Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -0.17%, SMA50 6.16%, SMA200 46.52%). The stock’s 14-day RSI is 50.63 (neutral), while the ATR of 1.45 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -12.11% below its high and over 198.53% above its low. Average 10-day trading volume of 77.30 thousand shares is below the 3-month average of 95.60 thousand, indicating normal recent market interest.

BrainsWay Ltd. has 18.91 million shares outstanding. The public float is 25.94 million shares, elevated short interest at 1.63% of float. This equals 191.66 thousand shares. The short ratio is 2.44 days. Institutional investors hold 33.19% of the float. Insiders own 6.4%.

Wall Street analysts project EPS growth of 53.24% annually over the next five years. The latest quarter delivered EPS of $0.04. The next quarter is forecast at $0.05. Next year's EPS is expected at $49.07. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $30.00 to $16.00. The high target offers 26.64% upside. The low target suggests -32.46% downside. The mean target is $20.50. This offers -13.47% upside. BrainsWay Ltd. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 11, 2025, missed forecasts by -63.64%. The prior quarter beat by 42.86%. Over the last six quarters, Apple has recorded several small beats. These include 300.0% in August 06, 2024.

BrainsWay Ltd. (NASDAQ:BWAY) closed at $23.69 USD, gaining $0.55 (2.38%) from the previous close of $23.14. The stock is currently mid-range between its 52-week high and low $7.84 and $26.63. With a market capitalization of about $464.60 million, BrainsWay Ltd. is classified as a small-cap and shows lower-than-market volatility (beta ~0.32). Key stats such as the average daily volume over the past year has been around 90.18 thousand shares, in line with its 52-week average. Headquartered in Jerusalem, None, BrainsWay Ltd. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Hadar Levy, the company employs approximately 120 people and listed since April 17, 2019. Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally.

Our AI price prediction model suggests that BrainsWay Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.74%, with price expected at $24.34 by March 16, 2026, within a range of $23.25 to $25.43 3-Month Outlook: Projected rise of 119.46%, reaching $51.99 by May 28, 2026, with a range of $51.67 to $52.66. 1-Year Outlook: Projected gain of 23.3%, with price at $29.21 by March 02, 2027, within a range of $28.43 to $29.94.

BrainsWay Ltd. (NASDAQ:BWAY) shares are up 16.35% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows BrainsWay Ltd. trading at a premium to the broader market with a P/E of 73.44. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $14.54, suggesting -38.62% downside. Our AI forecast model points to short-term strength (2.74% over two weeks), a medium-term rise (119.46% over three months), and a longer-term gain (23.3% over one year), with expected trading ranges indicating moderate volatility.

BrainsWay Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$9.77. This means the shares are trading below this model’s fair value.

BrainsWay Ltd. trades at a P/E ratio of 73.44, slightly above the S&P 500 average, with a price-to-sales ratio of 9.65 and a price-to-book ratio of 6.55 trading at moderately above to book value. The P/FCF stands at 25.82, also above market averages.